4D Molecular Therapeutics Q3 net loss widens on higher costs
4D Molecular Therapeutics Q3 net loss widens on higher costs
Overview
US gene therapy developer's Q3 revenue rose, beating analyst expectations
Q3 net loss and operating income missed analyst estimates
Collaboration revenue growth driven by clinical trial cost sharing and reimbursement from Otsuka
Outlook
Company expects topline data from 4FRONT-1 Phase 3 trial in Q2 2027
Topline data from 4FRONT-2 Phase 3 trial expected in H2 2027
Company expects cash position to fund operations into second half of 2028
Result Drivers
CLINICAL TRIAL COST SHARING - Increase in collaboration and license revenue was primarily due to clinical trial cost sharing and reimbursement from Otsuka
PHASE 3 TRIAL EXECUTION - Higher R&D expenses were mainly driven by execution of 4D-150 Phase 3 clinical trials in wet AMD
Company press release: ID:nGNXbghDsk
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Beat | $4.15 mln | $2.70 mln (9 Analysts) |
Q3 Net Loss | Miss | $78.06 mln | $74.21 mln (5 Analysts) |
Q3 Operating Income | Miss | -$81.22 mln | -$79.03 mln (6 Analysts) |
Q3 Loss Per Basic Share |
| $1.08 |
|
Q3 Operating Expenses |
| $85.36 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for 4D Molecular Therapeutics Inc is $28.00, about 115.6% above its November 11 closing price of $12.99
Reuters Recommended Reads
Nov 12 - Taysha Gene Therapies Q3 net loss widens on higher R&D costs
Nov 12 - UK-US MeiraGTx Q3 net loss widens as R&D costs rise
Nov 10 - Germany's Immatics Q3 revenue misses estimates, net loss widens on higher spending
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Recent news on 4D Molecular Therapeutics
See all news4D Molecular Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
4D Molecular Therapeutics Q3 net loss widens on higher costs
Brief: 4D Molecular Therapeutics Q3 Net Income USD -78.056 Million Vs. IBES Estimate USD -74.2 Million
4D Molecular Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
4D Molecular Therapeutics Q2 net loss widens